Thalassemia Market Size, Share & Trends Analysis Report By Therapeutic Class (Iron Chelating Drugs), By Pipeline (Gene Therapy), By Region (U.S., U.K., France, Germany, Italy, Spain, Japan), And Segment Forecasts, 2016 - 2022

Published: Mar, 2018 | Pages: 71 | Publisher: Grand View Research
Industry: Pharmaceutical | Report Format: Electronic (PDF)

The global thalassemia market size is expected to be valued at USD 3.53 billion by 2022, as per a new report by Grand View Research, Inc., exhibiting a CAGR of 10.8% during the forecast period. Increase in demand for a universal cure, rise in awareness about the disease, and technological advancements are likely to increase the adoption of gene therapies.

Thalassemia is a general term for a group of inheritable blood disorders, in which the body produces abnormal hemoglobin, resulting in destruction of red blood cells. This ultimately leads to anemia. There are two main types of thalassemia: alpha-thalassemia and beta-thalassemia, the latter being more serious. Beta-thalassemia is a common autosomal recessive disorder worldwide and it is relatively rare in U.S.

Increase in incidence of thalassemia is anticipated to fuel market growth. Despite technological advancements, unmet need for a reliable treatment option still exists. Treatment of thalassemia is mostly restricted to regular blood transfusions and iron chelation therapy. Drugs prescribed for thalassemia mostly cure symptoms and side effects such as anemia, iron overload, and vitamin deficiency. However, gene therapy is emerging as a reliable treatment option for the disease.

Prevalence of thalassemia is reported to increase gradually over the years across different regions. This can be attributed to population migration, intermarriages, and genetic and environmental factors prompting the condition and its implications.

Further key findings from the report suggest:

• The global thalassemia market is expected to expand at a lucrative CAGR of 10.8% over the forecast period because of improved safety and efficacy profiles of gene therapy

• India and Thailand are expected to offer lucrative growth opportunities for market expansion

• Some of the key players in the industry with promising pipeline products are bluebird bio, Inc.; Acceleron Pharma; Novartis AG; Incyte Corporation; Kiadis Pharma; Gamida Cell; and Celgene Corporation

• Blood transfusion and iron chelation therapies were the preferred treatment options for thalassemia in 2016, owing to their higher usage, ease, and affordability. However, the segments are likely to lose market share over the forecast period due to increase in adoption of curative gene therapy

• Regionally, among the seven major markets, EU5 held the dominant share in terms of revenue in 2016, followed by U.S. and Japan

• U.S. is expected to be the fastest growing region with a lucrative CAGR from 2016 to 2022 due to increase in prevalence of the disease and presence of well-established healthcare services

 Table of Contents

Chapter 1 Executive Summary

Chapter 2 Research Methodology
                  2.1 Information Procurement
                  2.2 Information or Data Analysis
                  2.3 Market Formulation & Validation

Chapter 3 Disease Primer and Epidemiology
                  3.1 Chapter Summary
                      3.1.1 Disease Primer
                      3.1.2 Epidemiology by Indications
                      3.1.3 Current Prevalence and Incidence for Seven Major Markets (U.S., Japan, & EU5) 

Chapter 4 Global Market Overview
                  4.1 Chapter Summary
                      4.1.1 Introduction and market overview
                      4.1.2 Market by therapeutic class
                      4.1.3 Market by treatments
                      4.1.4 Market size and forecast
                      4.1.5 Market share distribution for seven major markets (U.S., Japan, and EU5) 
                      4.1.6 Market dynamics among leading brands 
                  4.2 Patent Expiry Analysis
                  4.3 Drivers & Challenges
                      4.3.1 Drivers
                      4.3.2 Challenges
                  4.4 M&A, Deal Landscape (2013 - 2017 YTD) 
                  4.5 Emerging Markets
                  4.6 Therapeutic Sector SWOT

Chapter 5 Product Pipeline
                  5.1 Pipeline Landscape
                      5.1.1 Leading drugs in development (Chart summary) 
                      5.1.2 Key R&D trends (New targets & MoA) 
                  5.2 Promising Drug Candidates in Pipeline
                      5.2.1 Late-stage pipeline analysis
                      5.2.2 Profiles of the disruptive drugs/revolutionary treatments
                  5.3 Global Pipeline Forecast

Chapter 6 Competitive Landscape
                  6.1 Bluebird Bio
                      6.1.1 Company Overview
                      6.1.2 Current Product Portfolio - Major Products
                      6.1.3 Product Forecast Sales through 2022
                      6.1.4 Strategic Initiatives
                      6.1.5 Key Company News flow
                      6.1.6 Pipeline View
                      6.1.7 Catalysts & Events Calendar
                      6.1.8 SWOT Analysis
                  6.2 Novartis
                      6.2.1 Company Overview
                      6.2.2 Current Product Portfolio - Major Products
                      6.2.3 Product Forecast Sales through 2022
                      6.2.4 Strategic Initiatives
                      6.2.5 Key Company News Flow
                      6.2.6 Pipeline View
                      6.2.7 Catalysts & Events Calendar
                      6.2.8 SWOT Analysis
                  6.3 Kiadis Pharma 
                      6.3.1 Company Overview
                      6.3.2 Current Product Portfolio - Major Products
                      6.3.3 Product Forecast Sales Through 2022
                      6.3.4 Strategic Initiatives
                      6.3.5 Key Company News Flow
                      6.3.6 Pipeline View
                      6.3.7 SWOT Analysis
                  6.4 Acceleron Pharma / Celgene Corporation
                      6.4.1 Company Overview
                      6.4.2 Current Product Portfolio - Major Products
                      6.4.3 Strategic Initiatives
                      6.4.4 Key Company News Flow
                      6.4.5 Pipeline View
                      6.4.6 Catalysts & Events Calendar
                      6.4.7 SWOT Analysis

Chapter 7 Market Outlook
                  7.1 What the Future Holds
                  7.2 The Winner and Losers
                  7.3 Emerging Companies/New Technology Platforms
                  7.4 The Road Ahead

List of Tables

TABLE 1 Current Prevalence Rates and Numbers for Seven Major Markets - 2016
TABLE 2 Global Thalassemia Market Share Distribution (2016 - 2022)
TABLE 3 U.S. Patents for Current Thalassemia Drugs
TABLE 4 R&D Pipeline Overview
TABLE 5 Late Stage Pipeline
TABLE 6 Disruptive Drug : Lentiglobin
TABLE 7 Disruptive Drug : Luspatercept
TABLE 8 Pipeline Forecast
TABLE 9 Sales Forecast through 2022 (in $ Million) 
TABLE 10 Bluebird bio. Pipeline View
TABLE 11 Bluebird bio. Events Calendar
TABLE 12 Sales Forecast, 2016 - 2022 (in $ Million)
TABLE 13 Novartis Pipeline View
TABLE 14 Novartis Events Calendar
TABLE 15 Kiadis Pharma Pipeline View
TABLE 16 Acceleron Pharma Pipeline View
TABLE 17 Acceleron Pharma Events Calendar

List of Figures

FIG. 1 Market research process
FIG. 2 Information procurement
FIG. 3 Primary research pattern
FIG. 4 Market research approaches
FIG. 5 Value chain based sizing & forecasting
FIG. 6 QFD modelling for market share assessment
FIG. 7 Current prevalence rates for 7 major markets - 2016
FIG. 8 Current prevalence numbers for 7 major markets - 2016
FIG. 9 Global thalassemia market forecast (2016 - 2022)
FIG. 10 Global thalassemia market share distribution (2016 - 2022)
FIG. 11 Market share distribution for seven major markets (U.S., Japan, and EU5)
FIG. 12 SWOT analysis (Global thalassemia market)
FIG. 13 Bluebird bio. Pipeline view
FIG. 14 SWOT analysis (Bluebird bio)
FIG. 15 SWOT analysis (Novartis)
FIG. 16 SWOT analysis (Kiadis Pharma)
FIG. 17 Acceleron pharma pipeline view
FIG. 18 SWOT analysis (Acceleron Pharma/Celgene Corporation)